BMP6-Engineered MSCs Induce Vertebral Bone Repair in a Pig Model: A Pilot Study.

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Orthopedics

Background:

• Vertebral compression fractures (VCFs) in osteoporotic patients cause significant clinical and financial burdens.
• Current treatments for VCFs primarily manage symptoms, failing to address the underlying bone defect.
• A novel therapeutic approach is needed to promote bone regeneration in VCFs.

Purpose of the Study:

• To evaluate the efficacy of allogeneic, porcine mesenchymal stem cells overexpressing BMP6 (MSC-BMP6) in promoting bone regeneration.
• To assess the potential of MSC-BMP6 in a large animal model for treating VCFs.
• To compare the bone healing effects of MSC-BMP6 in fibrin gel versus fibrin gel alone.

Main Methods:

• Pilot study using a large animal pig model with induced vertebral defects.
• Implantation of allogeneic porcine MSC-BMP6 suspended in fibrin gel.
• Control group received fibrin gel only.
• In vivo evaluation using CT scans at 6 and 12 weeks.
• Ex vivo analysis of bone healing at 6 months.

Main Results:

• In vivo CT scans revealed significant bone regeneration in the MSC-BMP6 group within 6 weeks.
• The control group showed only minimal bone formation at the defect site.
• Ex vivo analysis at 6 months confirmed enhanced bone regeneration in the MSC-BMP6 group compared to controls.

Conclusions:

• Allogeneic MSC-BMP6 delivered in fibrin gel effectively induces bone regeneration in a preclinical VCF model.
• This gene-modified cell therapy represents a promising, potentially minimally invasive, strategy for treating osteoporosis-related VCFs.
• Further research may lead to revolutionary treatments for challenging bone defects.